• Explore /
  • Poster
  • / Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.

Abstract Poster

Authors

null

Danielle M. Pastor

Center for Immuno-Oncology, NCI, NIH, Bethesda, MD;

Danielle M. Pastor , Jason M. Redman , Charalampos S. Floudas , Elizabeth Lamping , Deneise C. Francis , Lisa M. Cordes , Jennifer L. Marte , Jeffrey Schlom , James L. Gulley , Julius Strauss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04491955

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 116)

DOI

10.1200/JCO.2023.41.4_suppl.116

Abstract #

116

Poster Bd #

F13

Abstract Disclosures

Similar Posters

First Author: Siqing Fu

First Author: Juan José Soto

First Author: Erlinda Maria Gordon

First Author: Ahmad A. Tarhini